drugset / Trial / NCT06503237
Safety and Efficacy of SWK002 in Patients With D2T-Rheumatoid Arthritis
Recruiting
18 enrolled
The First Affiliated Hospital of University of Science and Technology of China
NaSequentialOpen-labelTreatment
Summary
This is an open label, single-site, dose-escalation study in up to 18 participants with refractory rheumatoid arthritis. This study aims to evaluate the safety and efficacy of the treatment with Anti-CD19 CART.
Timeline
- Start
- 2023-11-09
- Primary completion
- 2026-03
- Completion
- 2026-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-CD19 CAR-T cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | anti-CD19 CAR-T cells | Cell therapy | 6e+06 cells/kg | Intravenous |